ZA202210526B - Rna constructs and uses thereof - Google Patents

Rna constructs and uses thereof

Info

Publication number
ZA202210526B
ZA202210526B ZA2022/10526A ZA202210526A ZA202210526B ZA 202210526 B ZA202210526 B ZA 202210526B ZA 2022/10526 A ZA2022/10526 A ZA 2022/10526A ZA 202210526 A ZA202210526 A ZA 202210526A ZA 202210526 B ZA202210526 B ZA 202210526B
Authority
ZA
South Africa
Prior art keywords
disclosed
rna constructs
same
cap
utr
Prior art date
Application number
ZA2022/10526A
Other languages
English (en)
Inventor
Sahin Ugur
Güler Alptekin
Kuhn Andreas
Muik Alexander
Vogel Annette
Walzer Kerstin
Witzel Sonja
Hein Stephanie
Türeci Özlem
Boros Gábor
Josefine Mahiny Azita
Reinholz Jonas
Kariko Katalin
Original Assignee
BioNTech SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=75438688&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA202210526(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by BioNTech SE filed Critical BioNTech SE
Publication of ZA202210526B publication Critical patent/ZA202210526B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/18011—Comoviridae
    • C12N2770/18022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/18011—Comoviridae
    • C12N2770/18034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/18011—Comoviridae
    • C12N2770/18071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Optics & Photonics (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
ZA2022/10526A 2020-04-22 2022-09-22 Rna constructs and uses thereof ZA202210526B (en)

Applications Claiming Priority (25)

Application Number Priority Date Filing Date Title
EP2020061239 2020-04-22
EP2020066968 2020-06-18
EP2020068174 2020-06-26
EP2020069805 2020-07-13
EP2020071733 2020-07-31
EP2020071839 2020-08-03
EP2020073668 2020-08-24
EP2020081544 2020-11-09
EP2020081981 2020-11-12
EP2020082601 2020-11-18
EP2020082989 2020-11-20
EP2020083435 2020-11-25
EP2020084342 2020-12-02
EP2020085145 2020-12-08
EP2020085653 2020-12-10
EP2020087844 2020-12-23
EP2021050027 2021-01-04
EP2021050874 2021-01-15
EP2021050875 2021-01-15
EP2021051772 2021-01-26
EP2021052572 2021-02-03
EP2021052716 2021-02-04
EP2021054622 2021-02-24
PCT/EP2021/059947 WO2021213924A1 (en) 2020-04-22 2021-04-16 Coronavirus vaccine
PCT/EP2021/060508 WO2021214204A1 (en) 2020-04-22 2021-04-22 Rna constructs and uses thereof

Publications (1)

Publication Number Publication Date
ZA202210526B true ZA202210526B (en) 2025-01-29

Family

ID=75438688

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA2022/10526A ZA202210526B (en) 2020-04-22 2022-09-22 Rna constructs and uses thereof
ZA2022/10524A ZA202210524B (en) 2020-04-22 2022-09-22 Coronavirus vaccine

Family Applications After (1)

Application Number Title Priority Date Filing Date
ZA2022/10524A ZA202210524B (en) 2020-04-22 2022-09-22 Coronavirus vaccine

Country Status (14)

Country Link
US (8) US11547673B1 (enExample)
EP (6) EP4138897A1 (enExample)
JP (5) JP7514206B2 (enExample)
KR (2) KR102813425B1 (enExample)
CN (7) CN118490818A (enExample)
AU (3) AU2021261471B2 (enExample)
BR (2) BR112022019781A2 (enExample)
CA (2) CA3174215A1 (enExample)
GB (3) GB2594365B (enExample)
IL (5) IL297419B2 (enExample)
MX (4) MX2022013254A (enExample)
TW (2) TW202508622A (enExample)
WO (2) WO2021213924A1 (enExample)
ZA (2) ZA202210526B (enExample)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
WO2016005004A1 (en) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilization of poly(a) sequence encoding dna sequences
FI4104687T3 (fi) 2015-09-21 2024-03-01 Trilink Biotechnologies Llc Koostumuksia ja menetelmiä 5-huputettujen RNA:iden syntetisoimiseksi
JP7555123B2 (ja) 2018-10-09 2024-09-24 ザ ユニヴァーシティ オブ ブリティッシュ コロンビア 有機溶媒不含かつ劣化剤不含のトランスフェクション・コンピテント・ベシクルを含む組成物及びシステム並びにそれらに関連する方法
JP7621270B2 (ja) 2019-04-05 2025-01-24 アカデミア シニカ シアリダーゼ耐性糖およびその調製および使用方法
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
US11547673B1 (en) * 2020-04-22 2023-01-10 BioNTech SE Coronavirus vaccine
CN113527510A (zh) * 2020-04-22 2021-10-22 上海交通大学 融合蛋白分子及其制备方法和用途
WO2025056938A1 (en) 2023-09-11 2025-03-20 BioNTech SE Rna compositions for delivery of incretin agents
CN112029781B (zh) * 2020-08-14 2023-01-03 中山大学 一种新型冠状病毒SARS-CoV-2的安全型复制子系统及其应用
GB202017649D0 (en) * 2020-11-09 2020-12-23 Autolus Ltd Polypeptide
JP2023550094A (ja) * 2020-11-12 2023-11-30 ティースキャン セラピューティクス インコーポレイテッド Ｓａｒｓ－ｃｏｖ－２免疫優性ペプチドの構築物及びその使用
US11591544B2 (en) 2020-11-25 2023-02-28 Akagera Medicines, Inc. Ionizable cationic lipids
US20240156946A1 (en) 2020-12-22 2024-05-16 CureVac SE Rna vaccine against sars-cov-2 variants
EP4087938A2 (en) * 2021-01-27 2022-11-16 CureVac AG Method of reducing the immunostimulatory properties of in vitro transcribed rna
DK4319803T3 (da) 2021-04-08 2025-12-15 Vaxthera Sas Coronavirusvaccine omfattende et mosaikprotein
WO2022235853A1 (en) 2021-05-04 2022-11-10 BioNTech SE Immunogen selection
US20250222096A1 (en) * 2021-10-21 2025-07-10 BioNTech SE Coronavirus vaccine
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
CN116200403A (zh) * 2021-11-30 2023-06-02 石药集团巨石生物制药有限公司 预防突变株的新型冠状病毒mRNA疫苗
AU2022416574A1 (en) 2021-12-16 2024-07-04 Hcemm Nonprofit Kft. Vaccine preparation
KR20230095025A (ko) * 2021-12-20 2023-06-28 아이진 주식회사 변이 SARS-CoV-2 백신 조성물 및 이의 용도
CN114031675B (zh) * 2022-01-10 2022-06-07 广州市锐博生物科技有限公司 基于SARS-CoV-2的S蛋白的疫苗和组合物
TW202345863A (zh) * 2022-02-09 2023-12-01 美商現代公司 黏膜投與方法及調配物
EP4476546A1 (en) * 2022-02-11 2024-12-18 Attana AB Analytical method
CN116768987A (zh) * 2022-03-09 2023-09-19 中生复诺健生物科技(上海)有限公司 编码新型冠状病毒S蛋白的mRNA疫苗
WO2023172547A1 (en) * 2022-03-11 2023-09-14 National Health Research Institutes Nucleic acid-lipid nanoparticle and method using the same
AU2023237601A1 (en) * 2022-03-22 2024-09-05 Osivax Mrna vaccine compositions and their use
WO2023202711A1 (zh) * 2022-04-22 2023-10-26 仁景(苏州)生物科技有限公司 一种基于新型冠状病毒的mRNA疫苗
CN118900914A (zh) 2022-04-27 2024-11-05 上海瑞宏迪医药有限公司 核酸构建体及其应用
WO2023220693A1 (en) * 2022-05-12 2023-11-16 SunVax mRNA Therapeutics Inc. Synthetic self-amplifying mrna molecules with secretion antigen and immunomodulator
CN114989308B (zh) * 2022-05-12 2023-04-04 中国科学院微生物研究所 新冠病毒嵌合核酸疫苗及其用途
JP2025516674A (ja) 2022-05-13 2025-05-30 ビオンテック エスエー Ｈｉｖを標的とするｒｎａ組成物
WO2023220842A1 (en) * 2022-05-19 2023-11-23 Shenzhen Genius Biotech Service Co.,Ltd. A fusion protein as a subunit vaccine immunogen against sars-cov-2 and the preparation thereof
WO2023228116A1 (en) * 2022-05-24 2023-11-30 Access To Advanced Health Institute Intranasal administration of thermostable rna vaccines
KR20250031230A (ko) 2022-05-25 2025-03-06 아카제라 메디신즈, 인크. 핵산 전달을 위한 지질 나노입자 및 이의 사용 방법
US11654121B1 (en) 2022-06-22 2023-05-23 Flagship Pioneering Innovations Vi, Llc Combination therapies for the treatment of viral infections
WO2023250111A1 (en) 2022-06-22 2023-12-28 Flagship Pioneering Innovations Vi, Llc Combination therapies for the treatment of viral infections
CN114934056B (zh) * 2022-06-24 2023-10-20 仁景(苏州)生物科技有限公司 一种基于新型冠状病毒奥密克戎突变株的mRNA疫苗
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
WO2024014770A1 (ko) * 2022-07-14 2024-01-18 엠큐렉스 주식회사 mRNA 백신 및 치료제의 제조를 위한 변형된 RNA
KR102918706B1 (ko) 2022-07-14 2026-01-29 엠큐렉스 주식회사 mRNA 백신 및 치료제의 제조를 위한 변형된 RNA
WO2024017253A1 (zh) * 2022-07-19 2024-01-25 深圳深信生物科技有限公司 新型冠状病毒S蛋白的mRNA及其应用
CN117414418A (zh) * 2022-07-19 2024-01-19 深圳深信生物科技有限公司 一种新型冠状病毒变异株的mRNA疫苗及其应用
WO2024026287A2 (en) * 2022-07-25 2024-02-01 University Of Utah Research Foundation Synthesis of substoichiometric chemically modified mrnas by in vitro transcription
CN115716866A (zh) * 2022-09-30 2023-02-28 珠海丽凡达生物技术有限公司 新型冠状病毒疫苗及其制备方法和应用
WO2024057237A1 (en) 2022-09-16 2024-03-21 Pfizer Inc. Lipid nanoparticles
WO2024075022A2 (en) 2022-10-04 2024-04-11 BioNTech SE Rna constructs and uses thereof
IL319682A (en) 2022-10-06 2025-05-01 BioNTech SE RNA complexes targeting claudin-18.2
TW202430206A (zh) 2022-10-17 2024-08-01 德商拜恩技術股份公司 組合疫苗
CN115869332A (zh) * 2022-10-27 2023-03-31 北京新合睿恩生物医疗科技有限公司 递送至体内后在肝脏少表达的mRNA药物及其制备方法
US12186389B2 (en) 2022-10-28 2025-01-07 Glaxosmithkline Biologicals Sa Nucleic acid base vaccine against emerging SARS-CoV-2 variants
CN118045169A (zh) * 2022-11-10 2024-05-17 中国科学院化学研究所 脂质-带电分子偶联物、可吸入式脂质纳米颗粒及其制备方法和应用
WO2024109866A1 (zh) 2022-11-24 2024-05-30 苏州艾博生物科技有限公司 提高蛋白表达量的utr分子
CN120435560A (zh) * 2022-12-16 2025-08-05 深圳深信生物科技有限公司 提高rna分子翻译效率和/或稳定性的utr及其应用
WO2024141955A1 (en) 2022-12-28 2024-07-04 BioNTech SE Rna compositions targeting hiv
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2024153324A1 (en) 2023-01-18 2024-07-25 BioNTech SE Rna formulations for pharmaceutical use
WO2024170652A1 (en) 2023-02-14 2024-08-22 Radiovaxx Gmbh Drug and treatment method
CN116410992A (zh) * 2023-03-10 2023-07-11 北京新合睿恩生物医疗科技有限公司 预防和/或治疗新型冠状病毒的mRNA、疫苗及其制备方法和应用
CN115998714B (zh) * 2023-03-20 2023-06-30 威瑞生物科技(昆明)有限责任公司 一种脂质纳米颗粒、递送系统及递送系统的制备方法
WO2024197098A2 (en) * 2023-03-20 2024-09-26 Cartesian Therapeutics, Inc. Local conditioning of lymph nodes with diffusion-limited particles for in vivo car therapy
WO2024215612A2 (en) 2023-04-08 2024-10-17 Roc Biomedical Inc. Methods and compositions for targeted delivery by polymersomes
WO2024215614A2 (en) * 2023-04-08 2024-10-17 Rock Biomedical Inc. Methods and compositions for dendritic cell targeting nano-delivery
EP4694919A1 (en) * 2023-04-14 2026-02-18 BioNTech SE Rna for preventing or treating tuberculosis
EP4711466A1 (en) * 2023-04-28 2026-03-18 Xianwei (Hainan) Biotechnology Co. Ltd. Engineered mrna and use thereof
KR20260013456A (ko) 2023-05-17 2026-01-28 락 바이오메디컬 인크. Mgat1 결핍 세포 및 이의 용도
WO2024245344A1 (zh) * 2023-05-30 2024-12-05 石药集团巨石生物制药有限公司 预防新型冠状病毒奥密克戎突变株的mRNA疫苗
TW202515531A (zh) 2023-07-07 2025-04-16 美商輝瑞股份有限公司 兩親性ｔｌｒ７／８佐劑及其用途
WO2025017029A1 (en) * 2023-07-17 2025-01-23 Eleven Therapeutics Ltd Non-natural building blocks for enhanced translation and stability of mrna
WO2025027579A2 (en) 2023-08-03 2025-02-06 BioNTech SE Rna compositions targeting hiv
WO2025027576A2 (en) 2023-08-03 2025-02-06 BioNTech SE Rna compositions targeting hiv
CN117224662B (zh) * 2023-08-24 2025-05-16 北京悦康科创医药科技股份有限公司 测定多价新冠mRNA疫苗各组分含量的方法
TW202526022A (zh) * 2023-09-06 2025-07-01 美商垂林克生物技術有限責任公司 帽類似物及其使用方法
WO2025057088A1 (en) 2023-09-11 2025-03-20 BioNTech SE Rna compositions for delivery of incretin agents
EP4689074A1 (en) * 2023-10-13 2026-02-11 SmartCella Solutions AB Methods and compositions for delivery of unmodified mrna constructs using mesenchymal stem cells
WO2025179238A2 (en) 2024-02-23 2025-08-28 BioNTech SE Coronavirus vaccine
WO2025201315A1 (zh) * 2024-03-25 2025-10-02 南京金斯瑞生物科技有限公司 利用自复制rna制备与多次跨膜蛋白特异结合的抗体的方法
CN118389495B (zh) * 2024-06-24 2024-10-01 北京悦康科创医药科技股份有限公司 一种核糖修饰的加帽类似物及其应用
EP4650358A3 (en) 2024-04-26 2026-01-14 Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. Ribose-modified cap analog and use thereof
KR102832944B1 (ko) 2024-12-27 2025-07-15 대한민국 제2형 중증급성호흡기증후군 코로나바이러스 변이들의 공통 서열을 포함하는 코로나바이러스감염증-19 범용 백신 조성물

Family Cites Families (368)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4898278A (en) 1986-12-05 1990-02-06 Nalge Company Storage container
JPH10113117A (ja) 1996-10-11 1998-05-06 Tomoji Tanaka 保冷箱
WO1998051278A2 (en) 1997-05-14 1998-11-19 Inex Pharmaceuticals Corporation High efficiency encapsulation of charged therapeutic agents in lipid vesicles
AU9319398A (en) 1997-09-19 1999-04-05 Sequitur, Inc. Sense mrna therapy
WO2000056749A1 (en) 1999-03-24 2000-09-28 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services N-acylphosphoramidites and their use in oligonucleotide synthesis
US6381981B1 (en) 2001-05-02 2002-05-07 Advanced Tissue Sciences, Inc. Container for shipping and storing frozen products
EP2842964A1 (de) 2001-06-05 2015-03-04 Curevac GmbH Virtuelles Verfahren zur Ermittlung einer modifzierten mRNA-Sequenz
US20030082357A1 (en) 2001-09-05 2003-05-01 Cem Gokay Multi-layer core for vacuum insulation panel and insulated container including vacuum insulation panel
US7074596B2 (en) 2002-03-25 2006-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse mRNA cap analogues
AU2003245729A1 (en) 2002-06-27 2004-01-19 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating a cytotoxic t lymphocyte immune response
DE60334618D1 (de) 2002-06-28 2010-12-02 Protiva Biotherapeutics Inc Verfahren und vorrichtung zur herstellung von liposomen
DE10229872A1 (de) 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
US8575110B2 (en) * 2003-02-17 2013-11-05 Alpha-O Peptides G Peptidic nanoparticles as drug delivery and antigen display systems
US7897744B2 (en) 2003-04-28 2011-03-01 The Public Health Agency Of Canada SARS virus nucleotide and amino acid sequences and uses thereof
US20050002953A1 (en) 2003-05-06 2005-01-06 Jens Herold SARS-coronavirus virus-like particles and methods of use
MXPA05012811A (es) 2003-06-10 2006-02-13 Nokia Corp Metodo y aparato para conmutar una estacion movil entre transmisiones autonomas y programadas.
CA2532196A1 (en) 2003-06-18 2005-01-20 Chinese National Human Genome Center At Shanghai Characterization of the earliest stages of the severe acute respiratory syndrome (sars) virus and uses thereof
WO2005012337A2 (en) 2003-07-15 2005-02-10 Crucell Holland B.V. Antigenic peptides of sars coronavirus and uses thereof
SG128680A1 (en) 2003-07-22 2007-01-30 Crucell Holland Bv Binding molecules against sars-coronavirus and uses thereof
WO2005013904A2 (en) 2003-08-04 2005-02-17 University Of Massachusetts Sars nucleic acids, proteins, vaccines, and uses thereof
TW200515917A (en) * 2003-09-15 2005-05-16 Us Government Methods and compositions for the generation of a protective immune response against SARS-COV
US7129042B2 (en) 2003-11-03 2006-10-31 Diagnostic Hybrids, Inc. Compositions and methods for detecting severe acute respiratory syndrome coronavirus
EP2361974A1 (fr) 2003-12-02 2011-08-31 Institut Pasteur Utilisation des proteines et des peptides codés par le genome d'une nouvelle souche de coronavirus associé au SRAS
US20050178142A1 (en) 2004-02-17 2005-08-18 Perry Ralph J. 96 hour duration insulated cryo-pack for maintaining -40 degree fahrenheit
EP1751178A2 (en) 2004-06-04 2007-02-14 Institut Pasteur Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with sars corona virus spike protein
US7870748B2 (en) 2005-02-25 2011-01-18 Byrne Kathleen H Method for controlled rate freezing and long term cryogenic storage
EP1882392A4 (en) 2005-05-10 2009-07-01 Monsanto Technology Llc GENES AND THEIR USES FOR PLANT IMPROVEMENTS
EP1912679A4 (en) 2005-06-15 2009-07-29 Massachusetts Inst Technology AMINOUS LIPIDS AND ITS USES
RS63964B1 (sr) 2005-08-23 2023-03-31 Univ Pennsylvania Rnk koja sadrži modifikovane nukleozide i postupci za njenu upotrebu
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
WO2008016473A2 (en) 2006-07-28 2008-02-07 Applera Corporation Dinucleotide mrna cap analogs
US8865398B2 (en) 2006-09-01 2014-10-21 Abbott Laboratories Combination hepatitis C virus antigen and antibody detection method
DE102006051516A1 (de) 2006-10-31 2008-05-08 Curevac Gmbh (Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins
DK2167523T3 (da) 2007-06-19 2014-09-08 Univ Louisiana State Syntese og anvendelse af anti-reverse phosphorothioatanaloger af messenger-rna-cappen
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
CA2721333C (en) 2008-04-15 2020-12-01 Protiva Biotherapeutics, Inc. Novel lipid formulations for nucleic acid delivery
PL215513B1 (pl) 2008-06-06 2013-12-31 Univ Warszawski Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka
AU2015210364B2 (en) 2008-10-09 2017-03-09 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
GB0818663D0 (en) * 2008-10-10 2008-11-19 Ark Therapeutics Ltd Gene regulation and its use in therapy
WO2010077717A1 (en) 2008-12-09 2010-07-08 Novavax, Inc. Modified rsv f proteins and methods of their use
US20120101148A1 (en) 2009-01-29 2012-04-26 Alnylam Pharmaceuticals, Inc. lipid formulation
WO2011005799A2 (en) 2009-07-06 2011-01-13 Novartis Ag Self replicating rna molecules and uses thereof
EP2281579A1 (en) 2009-08-05 2011-02-09 BioNTech AG Vaccine composition comprising 5'-Cap modified RNA
ME03091B (me) 2009-12-01 2019-01-20 Translate Bio Inc Isporuka irnk za povećanje ekspresije proteina i enzima u humanim genetskim oboljenjima
JP5940064B2 (ja) 2010-07-06 2016-06-29 ノバルティス アーゲー 低用量のｒｎａを用いた大型哺乳動物の免疫化
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
AU2015210336B2 (en) 2010-08-17 2017-05-25 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
HRP20221048T1 (hr) * 2010-08-31 2022-11-11 Glaxosmithkline Biologicals Sa Mali liposomi za isporuku rna koja kodira imunogen
DK4108671T3 (da) 2010-10-01 2025-01-06 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
CA2835428A1 (en) 2011-05-17 2012-11-22 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof for non-human vertebrates
PT2717893T (pt) 2011-06-08 2019-08-20 Translate Bio Inc Composições de nanopartículas lipídicas e métodos para transferência de arnm
EP3384938A1 (en) 2011-09-12 2018-10-10 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP6113737B2 (ja) 2011-10-03 2017-04-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
US20140308304A1 (en) 2011-12-07 2014-10-16 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
WO2013130161A1 (en) 2011-12-14 2013-09-06 modeRNA Therapeutics Methods of responding to a biothreat
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
CA2859691A1 (en) 2011-12-21 2013-06-27 Moderna Therapeutics, Inc. Methods of increasing the viability or longevity of an organ or organ explant
WO2013120499A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
RU2658490C2 (ru) 2012-03-27 2018-06-21 Кьюрвак Аг Искусственные молекулы нуклеиновых кислот для улучшенной экспрессии белков или пептидов
EP3578659B1 (en) 2012-03-27 2023-11-01 CureVac SE Artificial nucleic acid molecules for improved protein or peptide expression
US20150050354A1 (en) * 2012-04-02 2015-02-19 Moderna Therapeutics, Inc. Modified polynucleotides for the treatment of otic diseases and conditions
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
EP2834259A4 (en) 2012-04-02 2016-08-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES
US10501513B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
WO2014028429A2 (en) 2012-08-14 2014-02-20 Moderna Therapeutics, Inc. Enzymes and polymerases for the synthesis of rna
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
AU2013355258A1 (en) 2012-12-07 2015-06-11 Alnylam Pharmaceuticals, Inc. Improved nucleic acid lipid particle formulations
EP2931319B1 (en) 2012-12-13 2019-08-21 ModernaTX, Inc. Modified nucleic acid molecules and uses thereof
US20150315541A1 (en) 2012-12-13 2015-11-05 Moderna Therapeutics, Inc. Modified polynucleotides for altering cell phenotype
EP3578200A1 (en) 2013-02-22 2019-12-11 CureVac AG Combination of vaccination and inhibition of the pd-1 pathway
CN105073135A (zh) 2013-02-22 2015-11-18 库瑞瓦格有限责任公司 疫苗接种和抑制pd-1途径的组合
WO2014164253A1 (en) 2013-03-09 2014-10-09 Moderna Therapeutics, Inc. Heterologous untranslated regions for mrna
WO2014159813A1 (en) 2013-03-13 2014-10-02 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
WO2014152659A1 (en) 2013-03-14 2014-09-25 Shire Human Genetic Therapies, Inc. Quantitative assessment for cap efficiency of messenger rna
KR20150128687A (ko) 2013-03-14 2015-11-18 샤이어 휴먼 지네틱 테라피즈 인크. 메신저 rna의 정제 방법
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
WO2014152030A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Removal of dna fragments in mrna production process
US20160017313A1 (en) 2013-03-15 2016-01-21 Moderna Therapeutics, Inc. Analysis of mrna heterogeneity and stability
EP3578663A1 (en) 2013-03-15 2019-12-11 ModernaTX, Inc. Manufacturing methods for production of rna transcripts
CN105143456A (zh) 2013-03-15 2015-12-09 不列颠哥伦比亚大学 用于转染的脂质纳米粒子和相关方法
WO2014144767A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Ion exchange purification of mrna
US11377470B2 (en) 2013-03-15 2022-07-05 Modernatx, Inc. Ribonucleic acid purification
US20160032273A1 (en) 2013-03-15 2016-02-04 Moderna Therapeutics, Inc. Characterization of mrna molecules
TW201534578A (zh) 2013-07-08 2015-09-16 Daiichi Sankyo Co Ltd 新穎脂質
SG11201510747RA (en) 2013-08-21 2016-03-30 Curevac Ag Method for increasing expression of rna-encoded proteins
EP3450561A1 (en) 2013-08-21 2019-03-06 CureVac AG Method for increasing expression of rna-encoded proteins
EP3052511A4 (en) 2013-10-02 2017-05-31 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
AU2014337156A1 (en) 2013-10-18 2016-05-12 Modernatx, Inc. Compositions and methods for tolerizing cellular systems
EP3062798B1 (en) 2013-11-01 2020-05-06 CureVac AG Modified rna with decreased immunostimulatory properties
ES2806575T3 (es) 2013-11-01 2021-02-18 Curevac Ag ARN modificado con propiedades inmunoestimuladoras disminuidas
JP2016539944A (ja) * 2013-11-26 2016-12-22 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ 新規ｓａｒｓ免疫原性組成物
EP3540060A1 (en) 2013-12-30 2019-09-18 CureVac AG Methods for rna analysis
WO2015101416A1 (en) 2013-12-30 2015-07-09 Curevac Gmbh Methods for rna analysis
EP3556353A3 (en) 2014-02-25 2020-03-18 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
RU2021109685A (ru) 2014-04-23 2021-04-13 МОДЕРНАТиЭкс, ИНК. Вакцины на основе нуклеиновых кислот
KR102739894B1 (ko) 2014-04-25 2024-12-05 샤이어 휴먼 지네틱 테라피즈 인크. 메신저 rna 의 정제 방법
US10286086B2 (en) 2014-06-19 2019-05-14 Modernatx, Inc. Alternative nucleic acid molecules and uses thereof
IL289934B2 (en) 2014-06-25 2023-04-01 Acuitas Therapeutics Inc Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2016005004A1 (en) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilization of poly(a) sequence encoding dna sequences
EP3169693B1 (en) 2014-07-16 2022-03-09 ModernaTX, Inc. Chimeric polynucleotides
WO2016010840A1 (en) 2014-07-16 2016-01-21 Novartis Ag Method of encapsulating a nucleic acid in a lipid nanoparticle host
JP2017523777A (ja) 2014-07-17 2017-08-24 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． ポリヌクレオチドの末端修飾
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
EP4324473A3 (en) 2014-11-10 2024-05-29 ModernaTX, Inc. Multiparametric nucleic acid optimization
EP4241784A3 (en) 2014-12-12 2023-11-15 CureVac SE Artificial nucleic acid molecules for improved protein expression
US20180000953A1 (en) 2015-01-21 2018-01-04 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
WO2016164762A1 (en) 2015-04-08 2016-10-13 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor egf-a and intracellular domain mutants and methods of using the same
CN107567497A (zh) 2015-04-17 2018-01-09 库瑞瓦格股份公司 Rna的冻干
EP3289083A4 (en) 2015-04-27 2018-12-19 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
EP3294885B1 (en) 2015-05-08 2020-07-01 CureVac Real Estate GmbH Method for producing rna
EP3297682B1 (en) 2015-05-20 2021-07-14 CureVac AG Dry powder composition comprising long-chain rna
WO2016184575A1 (en) 2015-05-20 2016-11-24 Curevac Ag Dry powder composition comprising long-chain rna
WO2016193206A1 (en) 2015-05-29 2016-12-08 Curevac Ag A method for producing and purifying rna, comprising at least one step of tangential flow filtration
EP3307305A4 (en) 2015-06-10 2019-05-22 Modernatx, Inc. TARGETED ADAPTIVE VACCINES
EP4218805A1 (en) 2015-07-21 2023-08-02 ModernaTX, Inc. Infectious disease vaccines
WO2017015457A1 (en) 2015-07-21 2017-01-26 Modernatx, Inc. Ebola vaccine
US20190008887A1 (en) 2015-07-30 2019-01-10 ModernaTX Inc. Multimeric mrna
EP3328394A4 (en) 2015-07-30 2019-03-13 ModernaTX, Inc. CONCATEMEE peptide epitope RNAs
CN108138187B (zh) 2015-08-10 2022-07-19 库瑞瓦格房地产有限公司 增加环状dna分子复制的方法
WO2017031241A1 (en) 2015-08-17 2017-02-23 Modernatx, Inc. Rna mapping/fingerprinting
WO2017031232A1 (en) 2015-08-17 2017-02-23 Modernatx, Inc. Methods for preparing particles and related compositions
WO2017036889A1 (en) * 2015-08-28 2017-03-09 Biontech Rna Pharmaceuticals Gmbh Method for reducing immunogenicity of rna
EP3350157B1 (en) 2015-09-17 2022-01-05 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
WO2017049286A1 (en) 2015-09-17 2017-03-23 Moderna Therapeutics, Inc. Polynucleotides containing a morpholino linker
PL3350333T3 (pl) 2015-09-17 2022-03-07 Modernatx, Inc. Polinukleotydy zawierające region stabilizujący ogon
FI4104687T3 (fi) 2015-09-21 2024-03-01 Trilink Biotechnologies Llc Koostumuksia ja menetelmiä 5-huputettujen RNA:iden syntetisoimiseksi
AU2016336344A1 (en) 2015-10-05 2018-04-19 Modernatx, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
WO2017059902A1 (en) * 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
JP2018530587A (ja) 2015-10-16 2018-10-18 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． ｍＲＮＡキャップ類似体およびｍＲＮＡキャッピングの方法
WO2017066789A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs with modified sugar
WO2017066797A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Trinucleotide mrna cap analogs
ES2914225T3 (es) 2015-10-16 2022-06-08 Modernatx Inc Análogos de cap de ARNm con enlace de fosfato modificado
CA3002819A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Sexually transmitted disease vaccines
JP7687767B2 (ja) 2015-10-22 2025-06-03 モデルナティエックス インコーポレイテッド 呼吸器合胞体ウイルスワクチン
CA3003103A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Broad spectrum influenza virus vaccine
BR112018008090A2 (pt) 2015-10-22 2018-11-13 Modernatx Inc vacina de vírus do herpes simplex.
MA47016A (fr) 2015-10-22 2018-08-29 Modernatx Inc Vaccins contre les virus respiratoires
CA3002922A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
CA3003090A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Cancer vaccines
JP6925688B2 (ja) 2015-10-22 2021-08-25 モデルナティーエックス， インコーポレイテッド 水痘帯状疱疹ウイルス（ｖｚｖ）のための核酸ワクチン
EP3364950A4 (en) 2015-10-22 2019-10-23 ModernaTX, Inc. VACCINES AGAINST TROPICAL DISEASES
RS63986B1 (sr) 2015-10-28 2023-03-31 Acuitas Therapeutics Inc Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina
WO2017100551A1 (en) 2015-12-09 2017-06-15 Alexion Pharmaceuticals, Inc. HETEROLOGOUS UTR SEQUENCES FOR ENHANCED mRNA EXPRESSION
ES2924407T3 (es) 2015-12-10 2022-10-06 Modernatx Inc Composiciones y procedimientos para el suministro de agentes terapéuticos
WO2017106799A1 (en) 2015-12-17 2017-06-22 Modernatx, Inc. POLYNUCLEOTIDES ENCODING METHYLMALONYL-CoA MUTASE
SI3394030T1 (sl) 2015-12-22 2022-04-29 Modernatx, Inc. Sestave za doziranje sredstev v celice
US10465190B1 (en) 2015-12-23 2019-11-05 Modernatx, Inc. In vitro transcription methods and constructs
GB2546257A (en) 2016-01-08 2017-07-19 The Wool Packaging Company Ltd Temperature controlled packaging and transportation method
EP3405579A1 (en) 2016-01-22 2018-11-28 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
WO2017162266A1 (en) * 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Rna replicon for versatile and efficient gene expression
EP3442590A2 (en) 2016-04-13 2019-02-20 Modernatx, Inc. Lipid compositions and their uses for intratumoral polynucleotide delivery
US11078247B2 (en) 2016-05-04 2021-08-03 Curevac Ag RNA encoding a therapeutic protein
ES2973443T3 (es) 2016-05-18 2024-06-20 Modernatx Inc Polinucleótidos que codifican galactosa-1-fosfato uridililtransferasa para el tratamiento de galactosemia de tipo 1
EP3458108A4 (en) 2016-05-18 2020-04-22 ModernaTX, Inc. POLYNUCLEOTIDES ENCODING A CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS
EP3458106A4 (en) 2016-05-18 2020-03-18 Modernatx, Inc. POLYNUCLEOTIDS FOR CODING LIPOPROTEIN LIPASE FOR TREATING HYPERLIPIDEMIA
EP3458081A1 (en) 2016-05-18 2019-03-27 Modernatx, Inc. Polynucleotides encoding citrin for the treatment of citrullinemia type 2
CA3024507A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding .alpha.-galactosidase a for the treatment of fabry disease
US20200085916A1 (en) 2016-05-18 2020-03-19 Modernatx, Inc. Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria
KR102533456B1 (ko) 2016-05-18 2023-05-17 모더나티엑스, 인크. 릴랙신을 인코딩하는 폴리뉴클레오타이드
WO2017201317A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polyribonucleotides containing reduced uracil content and uses thereof
MA45037A (fr) 2016-05-18 2019-03-27 Modernatx Inc Polythérapie à base d'arnm pour le traitement du cancer
MA45052A (fr) 2016-05-18 2019-03-27 Modernatx Inc Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille
US20190298657A1 (en) 2016-05-18 2019-10-03 Modernatx, Inc. Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency
US20200069599A1 (en) 2016-06-14 2020-03-05 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
GB201611050D0 (en) 2016-06-24 2016-08-10 Softbox Systems Ltd A passive temperature control system for transport and storage containers
CA3036831A1 (en) 2016-09-14 2018-03-22 Modernatx, Inc. High purity rna compositions and methods for preparation thereof
EP3529255A1 (en) * 2016-10-19 2019-08-28 Arcturus Therapeutics, Inc. Trinucleotide mrna cap analogs
CA3041307A1 (en) 2016-10-21 2018-04-26 Giuseppe Ciaramella Human cytomegalovirus vaccine
WO2018081318A1 (en) 2016-10-25 2018-05-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion coronavirus spike proteins and their use
MA46643A (fr) 2016-10-26 2019-09-04 Modernatx Inc Méthodes et compositions pour le mappage d'arn
EP4714454A2 (en) * 2016-10-26 2026-03-25 Acuitas Therapeutics Inc. Lipid nanoparticle formulations
IL317855A (en) 2016-10-26 2025-02-01 Acuitas Therapeutics Inc mRNA vaccines with lipid nanoparticles
SG11201903674YA (en) 2016-10-26 2019-05-30 Modernatx Inc Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
US10925958B2 (en) 2016-11-11 2021-02-23 Modernatx, Inc. Influenza vaccine
MA50335A (fr) 2016-12-08 2020-08-19 Modernatx Inc Vaccins à acide nucléique contre des virus respiratoires
EP3555289A1 (en) 2016-12-13 2019-10-23 ModernaTX, Inc. Rna affinity purification
US11141476B2 (en) 2016-12-23 2021-10-12 Curevac Ag MERS coronavirus vaccine
US20180243225A1 (en) 2017-01-25 2018-08-30 Modernatx, Inc. Ebola/marburg vaccines
EP3577221A4 (en) 2017-02-01 2020-12-23 ModernaTX, Inc. Polynucleotide secondary structure
WO2018144775A1 (en) 2017-02-01 2018-08-09 Modernatx, Inc. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
AU2017397458B2 (en) 2017-02-01 2025-07-10 Modernatx, Inc. RNA cancer vaccines
WO2018151816A1 (en) 2017-02-16 2018-08-23 Modernatx, Inc. High potency immunogenic compositions
WO2018157009A1 (en) 2017-02-24 2018-08-30 Modernatx, Inc. Nucleic acid-based therapy of muscular dystrophies
WO2018160540A1 (en) 2017-02-28 2018-09-07 Sanofi Therapeutic rna
WO2018170245A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Broad spectrum influenza virus vaccine
WO2018170260A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Respiratory syncytial virus vaccine
ES2911186T3 (es) 2017-03-15 2022-05-18 Modernatx Inc Formas cristalinas de aminolípidos
FI3596041T3 (fi) 2017-03-15 2023-01-31 Yhdiste ja koostumuksia terapeuttisten aineiden antamiseen solun sisään
US11045540B2 (en) 2017-03-15 2021-06-29 Modernatx, Inc. Varicella zoster virus (VZV) vaccine
JP7332478B2 (ja) 2017-03-15 2023-08-23 モデルナティエックス インコーポレイテッド 脂質ナノ粒子製剤
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
CN118453840A (zh) 2017-03-15 2024-08-09 库尔生物制药有限公司 用于调节免疫应答的方法
EP3595676A4 (en) 2017-03-17 2021-05-05 Modernatx, Inc. RNA VACCINES AGAINST ZOONOSES
WO2018175783A1 (en) 2017-03-22 2018-09-27 Modernatx, Inc. Rna bacterial vaccines
EP3607074A4 (en) 2017-04-05 2021-07-07 Modernatx, Inc. REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY
WO2018188730A1 (en) * 2017-04-11 2018-10-18 Biontech Rna Pharmaceuticals Gmbh Rna for treatment of autoimmune diseases
US20200054737A1 (en) 2017-04-26 2020-02-20 Modema TX, Inc. Herpes simplex virus vaccine
US11485972B2 (en) 2017-05-18 2022-11-01 Modernatx, Inc. Modified messenger RNA comprising functional RNA elements
CN107033250B (zh) 2017-05-23 2020-01-21 山东省农业科学院奶牛研究中心 牛冠状病毒重组多表位抗原及其应用
US11786607B2 (en) 2017-06-15 2023-10-17 Modernatx, Inc. RNA formulations
WO2018232355A1 (en) 2017-06-15 2018-12-20 Modernatx, Inc. Rna antibodies
WO2019035998A1 (en) 2017-08-17 2019-02-21 Modernatx, Inc. SYSTEMS WITH CONTROL AND REGULATION OF FLUID PATH
EP3668979A4 (en) 2017-08-18 2021-06-02 Modernatx, Inc. METHOD OF HPLC ANALYSIS
US20200254086A1 (en) 2017-08-18 2020-08-13 Moderna TX, Inc. Efficacious mrna vaccines
ES2983060T3 (es) * 2017-08-18 2024-10-21 Modernatx Inc Variantes de ARN polimerasa
MA49914A (fr) 2017-08-18 2021-04-21 Modernatx Inc Procédés analytiques par hplc
MA50253A (fr) 2017-09-14 2020-07-22 Modernatx Inc Vaccins à arn contre le virus zika
US20190192646A1 (en) 2017-11-03 2019-06-27 Modernatx, Inc. Salmonella vaccines
WO2019092002A1 (en) 2017-11-07 2019-05-16 Valneva Se Pharmaceutical compositions for treatment or prevention of viral infections
GB201718660D0 (en) 2017-11-10 2017-12-27 Ucl Business Plc Improved liposome for mRNA delivery to cells
CA3083102A1 (en) 2017-11-21 2019-05-31 Modernatx, Inc. Epstein-barr virus vaccines
WO2019148101A1 (en) 2018-01-29 2019-08-01 Modernatx, Inc. Rsv rna vaccines
WO2019152557A1 (en) 2018-01-30 2019-08-08 Modernatx, Inc. Compositions and methods for delivery of agents to immune cells
US20210309995A1 (en) 2018-04-27 2021-10-07 Seattle Children's Hospital (dba Seattle Children's Research Institute) Homology-directed repair template design and delivery to edit hemoglobin-related mutations
WO2019232097A1 (en) 2018-05-30 2019-12-05 Translate Bio, Inc. Phosphoester cationic lipids
EP3813848A4 (en) 2018-06-27 2022-07-20 ModernaTX, Inc. EPITOPE SELECTION FOR PERSONALIZED CANCER VACCINE
TW202019955A (zh) 2018-07-31 2020-06-01 德商英麥提克生物技術股份有限公司 B*07 限制肽和肽組合的抗癌免疫治療和相關方法
AU2019338557A1 (en) 2018-09-13 2021-03-25 Modernatx, Inc. Modified mRNA for the treatment of progressive familial intrahepatic cholestasis disorders
WO2020061284A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Peg lipids and uses thereof
EP3853202A1 (en) 2018-09-19 2021-07-28 ModernaTX, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
EP4509118A3 (en) 2018-09-19 2025-05-14 ModernaTX, Inc. High-purity peg lipids and uses thereof
US12090235B2 (en) 2018-09-20 2024-09-17 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
CN113039174B (zh) 2018-10-02 2023-11-17 英特利亚治疗股份有限公司 可电离的胺脂质
KR102076917B1 (ko) * 2018-10-25 2020-02-13 연세대학교 산학협력단 자가조립 나노 입자를 제조하기 위한 유전자 재조합 발현 벡터 시스템 및 이를 이용하는 방법
WO2020097291A1 (en) 2018-11-07 2020-05-14 Modernatx, Inc. Rna cancer vaccines
CN111200358B (zh) 2018-11-19 2021-09-03 广东美的白色家电技术创新中心有限公司 抑制冷媒散热器的电磁干扰的系统及家用电器
MX2021008434A (es) 2019-01-14 2021-09-23 Genentech Inc Metodos para tratar el cancer con un antagonista de union al eje de pd-1 y una vacuna de arn.
JP7635131B2 (ja) 2019-01-31 2025-02-25 モデルナティエックス インコーポレイテッド 脂質ナノ粒子の調製方法
CA3130888A1 (en) 2019-02-20 2020-08-27 Modernatx, Inc. Rna polymerase variants for co-transcriptional capping
CN113874502A (zh) 2019-03-11 2021-12-31 摩登纳特斯有限公司 补料分批体外转录方法
US12070495B2 (en) 2019-03-15 2024-08-27 Modernatx, Inc. HIV RNA vaccines
CN114207134B (zh) 2019-03-25 2024-11-15 俄亥俄州国家创新基金会 工程化的mRNA序列及其用途
CA3142352A1 (en) 2019-05-31 2020-12-03 Modernatx, Inc. Expanded t cell assay
US20220387628A1 (en) 2019-06-24 2022-12-08 Modernatx, Inc. Messenger rna comprising functional rna elements and uses thereof
TWI817018B (zh) * 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物
CN110378000B (zh) 2019-07-11 2020-11-24 上海理工大学 基于强度场的结构静强度设计方法
GEP20257820B (en) 2019-08-14 2025-11-10 Acuitas Therapeutics Inc Improved lipid nanoparticles for delivery of nucleic acids
JP2022544416A (ja) 2019-08-14 2022-10-18 モデルナティエックス インコーポレイテッド ｉｎ ｖｉｔｒｏ転写の下流生成物を精製するプロセス
JP2022547313A (ja) 2019-09-11 2022-11-11 モデルナティエックス インコーポレイテッド ヒトサイトメガロウイルスワクチン
CA3154636A1 (en) * 2019-09-16 2021-03-25 Aalto University Foundation Sr Homogeneous fiber product based on bio-oil and / or water and method for their production
JP2022548957A (ja) 2019-09-19 2022-11-22 モデルナティエックス インコーポレイテッド キャップガイド及びｒｎａマッピングのためのその使用方法
GB201915905D0 (en) 2019-11-01 2019-12-18 Spybiotech Ltd Viruses with modified capsid proteins
WO2021138447A1 (en) 2019-12-31 2021-07-08 Elixirgen Therapeutics, Inc. Temperature-based transient delivery of nucleic acids and proteins to cells and tissues
WO2021142306A1 (en) 2020-01-10 2021-07-15 Modernatx, Inc. Variational autoencoder for biological sequence generation
WO2021147025A1 (en) 2020-01-22 2021-07-29 The University Of Hong Kong-Shenzhen Hospital Anti 2019-ncov vaccine
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
TW202142555A (zh) 2020-01-27 2021-11-16 美商諾瓦瓦克斯股份有限公司 冠狀病毒疫苗配製品
US20210228707A1 (en) 2020-01-28 2021-07-29 Modernatx, Inc. Coronavirus rna vaccines
AU2021213108A1 (en) * 2020-01-28 2022-08-18 Modernatx, Inc. Coronavirus RNA vaccines
JP2023513073A (ja) 2020-01-30 2023-03-30 モデルナティエックス インコーポレイテッド 呼吸器系ウイルス免疫化組成物
BR112022014808A2 (pt) 2020-01-31 2022-09-20 Beth Israel Deaconess Medical Ct Inc Composições e métodos para vacinas para prevenir e tratar infecção pelo coronavírus-sars-cov-2
WO2021155760A1 (zh) 2020-02-03 2021-08-12 康希诺生物股份公司 用于2019-nCoV型冠状病毒mRNA疫苗、制备方法及其应用
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
JP7793525B2 (ja) 2020-02-04 2026-01-05 キュアバック エスイー コロナウイルスワクチン
KR102848852B1 (ko) 2020-02-05 2025-08-20 샨시 진보 바이오-파르마시우티컬 씨오., 엘티디. 폴리펩티드, 이의 제조방법 및 용도
KR20220140528A (ko) 2020-02-07 2022-10-18 모더나티엑스, 인크. Sars-cov-2 mrna 도메인 백신
JP2023512833A (ja) 2020-02-07 2023-03-29 アールエヌエーイミューン、インコーポレイテッド 新型コロナウイルス感染症に対するｍＲＮＡワクチンの組成物及び方法
CN111592602B (zh) 2020-02-10 2021-03-02 中国科学院微生物研究所 一种β冠状病毒抗原、其制备方法和应用
JP2023513693A (ja) * 2020-02-11 2023-04-03 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ ＳＡＲＳ－ＣｏＶ－２ワクチン
WO2021163371A1 (en) 2020-02-12 2021-08-19 La Jolla Institute For Immunology Coronavirus t cell epitopes and uses thereof
MX2022009989A (es) 2020-02-13 2022-11-08 Pasteur Institut Composiciones inmunogenicas y vacunas para covid-19 vectorizadas por sarampion.
CN113186203B (zh) 2020-02-13 2022-12-30 斯微(上海)生物科技股份有限公司 治疗或者预防冠状病毒病的疫苗试剂
WO2021160346A1 (en) 2020-02-13 2021-08-19 Institut Pasteur Nucleic acid vaccine against the sars-cov-2 coronavirus
CA3167498A1 (en) 2020-02-14 2021-08-19 Anne De Groot T cell epitope clusters and related compositions useful in the prevention, diagnosis, and treatment of covid-19
GB2594683A (en) 2020-02-17 2021-11-10 Vaxbio Ltd Vaccine
CN111303254A (zh) 2020-02-20 2020-06-19 北京新创生物工程有限公司 新型冠状病毒（SARS-CoV-2）抗原检测试剂盒
CN110951756B (zh) 2020-02-23 2020-08-04 广州恩宝生物医药科技有限公司 表达SARS-CoV-2病毒抗原肽的核酸序列及其应用
CN110974950B (zh) 2020-03-05 2020-08-07 广州恩宝生物医药科技有限公司 一种用于预防SARS-CoV-2感染的腺病毒载体疫苗
US20210283244A1 (en) 2020-02-23 2021-09-16 Guangzhou N Biomed Ltd. Adenovirus-vectored vaccine for preventing sars-cov-2 infection
CN112300251B (zh) 2020-02-24 2022-04-05 成都威斯克生物医药有限公司 抗SARS-CoV-2感染的蛋白及疫苗
CN111218458B (zh) 2020-02-27 2020-11-20 珠海丽凡达生物技术有限公司 编码SARS-CoV-2病毒抗原的mRNA和疫苗及疫苗的制备方法
WO2021178306A1 (en) 2020-03-01 2021-09-10 Dynavax Technologies Corporation Coronavirus vaccines comprising a tlr9 agonist
US12269846B2 (en) 2020-03-05 2025-04-08 Swey-Shen Chen CoV-2 (CoV-n) antibody neutralizing and CTL vaccines using protein scaffolds and molecular evolution
US11213482B1 (en) 2020-03-05 2022-01-04 University of Pittsburgh—Of the Commonwealth System of Higher Educat SARS-CoV-2 subunit vaccine and microneedle array delivery system
EP4114458A4 (en) 2020-03-05 2024-04-17 New York Blood Center, Inc. IMMUNOGENIC COMPOSITIONS AGAINST CORONAVIRUS-2 RESPONSIBLE FOR SEVERE ACUTE RESPIRATORY SYNDROME
JP2023517644A (ja) * 2020-03-09 2023-04-26 アークトゥラス・セラピューティクス・インコーポレイテッド コロナウイルスワクチン組成物及び方法
US12285480B2 (en) 2020-03-11 2025-04-29 Nantcell, Inc. Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses
MX2022011394A (es) 2020-03-13 2022-10-13 Univ Oxford Innovation Ltd Composiciones y metodos para la induccion de una respuesta inmune.
CN111218459B (zh) 2020-03-18 2020-09-11 中国人民解放军军事科学院军事医学研究院 一种以人复制缺陷腺病毒为载体的重组新型冠状病毒疫苗
US20230136960A1 (en) 2020-03-19 2023-05-04 Nature's Toolbox, Inc. Novel MRNA-Based COVID-19 Multi-Valent Vaccine and Methods of Scaled Production of the Same
CN111088283B (zh) 2020-03-20 2020-06-23 苏州奥特铭医药科技有限公司 mVSV病毒载体及其病毒载体疫苗、一种基于mVSV介导的新冠肺炎疫苗
TW202200199A (zh) 2020-03-20 2022-01-01 美商百歐恩泰美國公司 冠狀病毒疫苗及使用方法
US20230167159A1 (en) 2020-03-20 2023-06-01 Kansas State University Research Foundation Sars-coronavirus 2 (sars-cov-2) subunit vaccine candidates
CN111560074B (zh) 2020-03-20 2021-07-09 中山大学 一种基于幽门螺旋杆菌铁蛋白的新型冠状病毒s蛋白单区域亚单位纳米疫苗
US20240210415A1 (en) 2020-03-24 2024-06-27 Icahn School Of Medicine At Mount Sinai Recombinant sars-cov-2 spike protein and uses thereof
GB202004493D0 (en) 2020-03-27 2020-05-13 Imp College Innovations Ltd Coronavirus vaccine
JPWO2021200800A1 (enExample) 2020-03-30 2021-10-07
US11559577B2 (en) 2020-03-31 2023-01-24 Engimata, Inc. Immunogenic composition forming a vaccine, and a method for its manufacture
WO2021201612A1 (ko) 2020-03-31 2021-10-07 주식회사 에스엘백시젠 신규 코로나바이러스 예방 및 치료용 백신 조성물
US11278617B2 (en) 2020-03-31 2022-03-22 Engimata, Inc Immunogenic composition forming a SARS-CoV-2 vaccine, and a method for its manufacture
WO2021202599A2 (en) 2020-04-01 2021-10-07 Valiant Biosciences, Llc Adeno-associated virus based compositions and related methods for inducing humoral immunity
CA3179038A1 (en) 2020-04-01 2021-10-07 Diosynvax Ltd Coronavirus vaccines
JP2023520506A (ja) 2020-04-01 2023-05-17 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド Ｓａｒｓ－ｃｏｖ－２に対する多層ｒｎａナノ粒子ワクチン
TW202202169A (zh) 2020-04-02 2022-01-16 中央研究院 預防嚴重急性呼吸症候群冠狀病毒第二型（ｓａｒｓ－ｃｏｖ－２）感染的生物可降解奈米複合物疫苗及方法
CN111748557B (zh) 2020-04-03 2022-03-11 苏州吉玛基因股份有限公司 抑制新型冠状病毒的小干扰核酸及组合物和应用
EP4126027A1 (en) 2020-04-03 2023-02-08 PepTC Vaccines Limited Coronavirus vaccine
GB202004974D0 (en) 2020-04-03 2020-05-20 Treos Bio Ltd Coronavirus vaccine
WO2021203044A2 (en) 2020-04-03 2021-10-07 Icahn School Of Medicine At Mount Sinai High-throughput assay for circulating antibodies against severe acute respiratory syndrome coronavirus 2
RU2747762C1 (ru) 2020-04-05 2021-05-13 Илья Владимирович Духовлинов Вакцина для профилактики или лечения коронавирусной инфекции на основе генетической конструкции
WO2021205455A1 (en) 2020-04-07 2021-10-14 Ramot At Tel-Aviv University Ltd. Sars-cov2 coronavirus reconstituted rbm and uses thereof
CN112023035A (zh) 2020-04-07 2020-12-04 中国医学科学院医学生物学研究所 一种以SARS-CoV-2病毒S蛋白RBD区为抗原的纳米疫苗及其制备
CN113874507A (zh) 2020-04-09 2021-12-31 苏州艾博生物科技有限公司 冠状病毒的核酸疫苗
WO2021211749A1 (en) 2020-04-14 2021-10-21 The Regents Of The University Of California Multi-epitope pan-coronavirus vaccine compositions
US20230310582A1 (en) 2020-04-14 2023-10-05 Duke University Sars-2 spike protein designs, compositions and methods for their use
WO2021209824A1 (en) 2020-04-17 2021-10-21 Institut Pasteur Methods and products for serological analysis of sars-cov-2 infection
EP4136095A1 (en) 2020-04-17 2023-02-22 Regents of the University of Minnesota Sars-cov-2 spike receptor binding domain and compositions and methods thereof
EP4135847A4 (en) 2020-04-17 2024-05-15 VLP Therapeutics, Inc. Coronavirus vaccine
CA3176320A1 (en) 2020-04-20 2021-10-28 Richard STRATFORD Sars-cov-2 vaccines
WO2021216738A2 (en) 2020-04-21 2021-10-28 Intima Bioscience, Inc. Compositions and methods of generating an immune response
WO2021212568A1 (zh) 2020-04-21 2021-10-28 苏州方科生物科技有限公司 新型冠状病毒特异性抗原肽及其用途
AU2021259612A1 (en) 2020-04-21 2022-11-10 Intima Bioscience, Inc. Cellular vaccine platform and methods of use
WO2021216743A2 (en) 2020-04-21 2021-10-28 Emory University Coronavirus vaccines, compositions, and methods related thereto
KR20230015351A (ko) 2020-04-22 2023-01-31 화이자 인코포레이티드 코로나바이러스 백신
US11547673B1 (en) 2020-04-22 2023-01-10 BioNTech SE Coronavirus vaccine
WO2021222304A1 (en) 2020-04-27 2021-11-04 Modernatx, Inc. Sars-cov-2 rna vaccines
KR102482994B1 (ko) 2020-04-29 2022-12-29 에스케이바이오사이언스(주) 사스-코로나바이러스-2 감염증 예방 또는 치료용 백신 조성물
IT202000009625A1 (it) 2020-04-30 2021-10-30 Takis S R L Polinucleotidi codificanti antigeni di sars-cov-2 e relativo uso in campo medico come vaccini.
WO2021223647A1 (en) 2020-05-06 2021-11-11 The University Of Hong Kong Compositions and methods for making and using vaccines against covid-19
WO2021226436A1 (en) 2020-05-07 2021-11-11 Translate Bio, Inc. Optimized nucleotide sequences encoding sars-cov-2 antigens
US20240123053A1 (en) 2020-05-07 2024-04-18 Bharat Biotech International Limited Coronavirus vaccine through nasal immunization
EP4105228A4 (en) 2020-05-11 2023-10-11 Hengda Biomedical Technology Co., Ltd. SARS-COV-2 ANTIGEN POLYPEPTIDE, RECOMBINANT ADENO-ASSOCIATED VIRUS THEREOF AND APPLICATION IN THE PRODUCTION OF A VACCINE
CN111518175B (zh) 2020-05-11 2021-02-26 广东珩达生物医药科技有限公司 Sars-cov-2抗原多肽及其重组腺相关病毒和在制备疫苗中的应用
EP4149540A4 (en) 2020-05-12 2024-06-12 Greffex, Inc. MANIPULATION OF CORONAVIRUS SPIKE PROTEINS AS VACCINE ANTIGENS, THEIR DESIGN AND USES
US20230142529A1 (en) 2020-05-15 2023-05-11 Modernatx, Inc. Rna formulations for high volume distribution
WO2021159130A2 (en) 2020-05-15 2021-08-12 Modernatx, Inc. Coronavirus rna vaccines and methods of use
US12331078B2 (en) 2020-05-18 2025-06-17 The Regents Of The University Of Colorado, A Body Corporate Stabilizing mutants of prefusion SARS-CoV-2 (COVID-19) spike protein and improved yeast surface display engineering platform for the same
CN111363858B (zh) 2020-05-26 2020-09-29 南京黎明生物制品有限公司 2019-nCoV S基因检测核酸组合物及试剂盒与生产方法
CN116322758A (zh) 2020-05-29 2023-06-23 库尔维科欧洲股份公司 基于核酸的组合疫苗
WO2021253172A1 (zh) 2020-06-15 2021-12-23 上海市公共卫生临床中心 利用受体识别域诱导抗新冠病毒中和抗体的方法
US10906944B2 (en) 2020-06-29 2021-02-02 The Scripps Research Institute Stabilized coronavirus spike (S) protein immunogens and related vaccines
WO2022003119A1 (en) 2020-07-01 2022-01-06 CEBINA GmbH Cross-reactive coronavirus vaccine
WO2022000845A1 (zh) 2020-07-01 2022-01-06 江苏省疾病预防控制中心(江苏省公共卫生研究院) 一种预防SARS-CoV-2的重组蛋白疫苗及其制备方法
WO2022006565A1 (en) 2020-07-03 2022-01-06 Kang Zhang Polypeptides, vaccine compositions, and use thereof for inducing immune response to sars-cov-2 in primates
GB2596820A (en) 2020-07-07 2022-01-12 Spicona Inc Combination vaccine
EP4178544A4 (en) 2020-07-08 2024-09-25 The Trustees of the University of Pennsylvania NUCLEOSIDE-MODIFIED RNA TO INDUCE AN IMMUNE RESPONSE AGAINST SARS-COV-2 VIRUS
CN111978377B (zh) 2020-07-09 2022-05-31 苏州和锐生物科技有限公司 Covid-19抗原、制备方法和应用
EP4178545A4 (en) 2020-07-10 2024-08-07 Engimata, Inc IMMUNOGENIC COMPOSITION FORMING A VACCINE AND METHOD OF MANUFACTURE THEREOF
CN112043825B (zh) 2020-07-13 2023-12-05 中国医学科学院医学生物学研究所 一种基于新型冠状病毒突刺蛋白s1区域预防新型冠状病毒感染的亚单位疫苗
CN111848753B (zh) 2020-07-20 2022-03-15 中国科学院过程工程研究所 新型冠状病毒抗原表位及其应用
RU2733834C1 (ru) 2020-07-28 2020-10-07 Федеральное бюджетное учреждение науки Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) Искусственный ген EctoS_SC2, кодирующий эктодомен гликопротеина S коронавируса SARS-CoV-2 с C-концевым тримеризующим доменом, рекомбинантная плазмида pStem-rVSV-EctoS_SC2, обеспечивающая экспрессию искусственного гена, и рекомбинантный штамм вируса везикулярного стоматита rVSV-EctoS_SC2, используемый для создания вакцины против коронавируса SARS-CoV-2
CN112028976A (zh) 2020-08-05 2020-12-04 上海裕隆生物科技有限公司 2019新型冠状病毒刺突蛋白受体结合结构域蛋白及应用
CN111939250B (zh) 2020-08-17 2022-07-29 郑州大学 一种预防covid-19的疫苗及其制备方法
RU2731342C9 (ru) 2020-08-22 2021-10-05 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Фармацевтическое средство и способ его использования для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома SARS-CoV-2 (варианты)
RU2731356C9 (ru) 2020-08-22 2021-10-05 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Экспрессионный вектор для создания иммунобиологического средства для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома SARS-CoV-2 (варианты)
CN112048005B (zh) 2020-09-04 2022-09-09 江苏省中国科学院植物研究所 新型冠状病毒s蛋白片段多倍体及其制备方法、检测试剂盒、疫苗及药物
CN112094327A (zh) 2020-09-25 2020-12-18 军事科学院军事医学研究院军事兽医研究所 基于新型冠状病毒rbd-sd1蛋白的截短体及其应用
CN112266411B (zh) 2020-09-25 2022-06-24 北京诺思兰德生物技术股份有限公司 一种新型冠状病毒疫苗及其应用
CN112226445B (zh) 2020-10-20 2021-05-11 成都欧林生物科技股份有限公司 编码SARS-CoV-2病毒刺突蛋白的核酸及其的应用
WO2022083768A1 (zh) 2020-10-23 2022-04-28 江苏省疾病预防控制中心(江苏省公共卫生研究院) 免疫原性组合物及其应用
CN112358533B (zh) 2020-10-30 2023-07-14 上海泽润生物科技有限公司 重组刺突蛋白及其制备方法和用途
CN112220920B (zh) 2020-10-30 2023-06-13 上海泽润生物科技有限公司 一种重组新型冠状病毒疫苗组合物
US20240041785A1 (en) 2020-11-16 2024-02-08 BioNTech SE Compositions and methods for stabilization of lipid nanoparticle mrna vaccines
CN114517205A (zh) 2020-11-20 2022-05-20 北京震旦鼎泰生物科技有限公司 融合基因及一种重组新型冠状病毒高效免疫鼎分子dna疫苗及其构建方法和应用
CN112480217B (zh) 2020-11-30 2022-04-08 广州阿格纳生物医药制造有限公司 基于SARS-CoV-2的S抗原蛋白的疫苗和组合物
CN112626089B (zh) 2020-12-08 2022-03-11 杭州百凌生物科技有限公司 一种SARS-CoV-2病毒S蛋白受体结合区域编码基因、抗体及应用
US20240156946A1 (en) 2020-12-22 2024-05-16 CureVac SE Rna vaccine against sars-cov-2 variants
CN112794884B (zh) 2020-12-28 2022-02-18 中国科学院微生物研究所 新型冠状病毒蛋白、制备方法及中和抗体检测试剂盒
CN112321688B (zh) 2021-01-06 2021-03-26 广东华南疫苗股份有限公司 稳定的冠状病毒重组蛋白二聚体及其表达载体
WO2022197624A1 (en) 2021-03-15 2022-09-22 Modernatx, Inc. Therapeutic use of sars-cov-2 mrna domain vaccines
CN116003496A (zh) * 2021-11-24 2023-04-25 南京吉迈生物技术有限公司 经修饰的mRNA5`-帽类似物

Also Published As

Publication number Publication date
US11925694B2 (en) 2024-03-12
EP4592306A2 (en) 2025-07-30
IL315743A (en) 2024-11-01
IL297417B2 (en) 2025-06-01
US11951185B2 (en) 2024-04-09
US20220249704A1 (en) 2022-08-11
IL297419B1 (en) 2024-10-01
BR112022019781A2 (pt) 2022-12-13
EP4139452A1 (en) 2023-03-01
IL297419A (en) 2022-12-01
US12133899B2 (en) 2024-11-05
WO2021214204A1 (en) 2021-10-28
TWI860474B (zh) 2024-11-01
CN115811986A (zh) 2023-03-17
AU2025200483A1 (en) 2025-02-20
AU2021261471A1 (en) 2022-11-17
AU2021260099A1 (en) 2022-11-24
CN118490818A (zh) 2024-08-16
BR112022019782A2 (pt) 2022-12-13
EP3901261A1 (en) 2021-10-27
GB202105481D0 (en) 2021-06-02
AU2021260099B2 (en) 2025-05-22
US20230075979A1 (en) 2023-03-09
CN113521269A (zh) 2021-10-22
TW202206096A (zh) 2022-02-16
CN115867654A (zh) 2023-03-28
US11547673B1 (en) 2023-01-10
JP2025063030A (ja) 2025-04-15
KR20230004735A (ko) 2023-01-06
MX2024009072A (es) 2024-07-30
JP7514206B2 (ja) 2024-07-10
KR102796212B1 (ko) 2025-04-17
EP4549449A2 (en) 2025-05-07
IL317516A (en) 2025-02-01
CA3173922A1 (en) 2021-10-28
CN116585464A (zh) 2023-08-15
MX2022013255A (es) 2023-01-24
JP7604519B2 (ja) 2024-12-23
US20220273820A1 (en) 2022-09-01
JP2023522246A (ja) 2023-05-29
CA3174215A1 (en) 2021-10-28
TW202508622A (zh) 2025-03-01
JP2021191743A (ja) 2021-12-16
GB2594364A (en) 2021-10-27
JP2023522249A (ja) 2023-05-29
CN113521268A (zh) 2021-10-22
MX2022013254A (es) 2023-01-24
US20240075165A1 (en) 2024-03-07
GB202105465D0 (en) 2021-06-02
US20240390524A1 (en) 2024-11-28
EP4138897A1 (en) 2023-03-01
IL315928A (en) 2024-11-01
GB2594365A (en) 2021-10-27
US11779659B2 (en) 2023-10-10
KR20230015350A (ko) 2023-01-31
KR102813425B1 (ko) 2025-05-28
AU2021261471B2 (en) 2024-10-24
EP3901260A1 (en) 2021-10-27
ZA202210524B (en) 2024-07-31
EP4592306A3 (en) 2025-10-08
MX2024011779A (es) 2024-11-08
IL297419B2 (en) 2025-02-01
GB202307565D0 (en) 2023-07-05
IL297417B1 (en) 2025-02-01
WO2021213924A1 (en) 2021-10-28
IL297417A (en) 2022-12-01
CN118121722A (zh) 2024-06-04
GB2594365B (en) 2023-07-05
US20250242059A1 (en) 2025-07-31
EP4549449A3 (en) 2025-08-13
JP2021185136A (ja) 2021-12-09
US20230073461A1 (en) 2023-03-09

Similar Documents

Publication Publication Date Title
MX2024011779A (es) Constructos de arn y usos de los mismos
WO2023073190A8 (en) Rna constructs and uses thereof
WO2000029561A3 (en) Nucleotide construct with optimised codons for an hiv genetic vaccine based on a primary, early hiv isolate and synthetic envelope
IL159637A (en) Preparations @ for use @ in medicine @ genes that contain and transform cd34 + cells
CA2420874A1 (en) Active ingredient combinations with insecticidal and acaricidal properties
MX2022001719A (es) Formulaciones de conjugados de benzazepina y usos de las mismas.
YU7804A (sh) Stabilni polimorf flibanserina,postupak za njegovo dobijanje u industrijskim razmerama i njegova primena za pripremanje lekova
GB2386072A (en) Novel vaccine
MX2022014161A (es) Vacunas contra sars-cov-2.
WO2004067710A3 (en) Compositions and methods for tissue specific targeting of lentivirus vectors
HUP0303126A2 (hu) Vektorok molekuláknak CD11b-t expresszáló sejtekhez történő szállítására
BR0314893A (pt) Vetor para vacina contra hpv e microrganismo transformado pelo vetor
WO2003054154A3 (en) Antisense modulation of mucin 1, transmembrane expression
WO2024075022A3 (en) Rna constructs and uses thereof
WO2002059156A3 (en) Therapeutic compounds structurally-linked to bacterial polypeptides
WO2002077017A3 (en) Medical uses of intercellular communication facilitating compounds
EP1712243A4 (en) GENE THERAPY FOR TUMOR USING A NEGATIVE CHAIN RNA VIRAL VECTOR ENCODING AN IMMUNOSTIMULATORY CYTOKINE
WO2023150638A3 (en) Omicron coronavirus vaccine constructs and methods of making and using same
ZA202209925B (en) Compositions and methods for treating pompe disease
PL357999A1 (en) Lhrh-antagonists, production and use thereof as medicament
WO2021158755A3 (en) Leptospiral proteins and uses thereof
EP1390388A4 (en) ANTISENSE MODULATION OF THE EXPRESSION OF THE INTERFERON GAMMA RECEPTOR 1
AU2001278884A1 (en) Anti-hiv and anti-tumor peptides and fragments of lysozyme
WO2023092100A3 (en) Methods of administering chimeric vaccines
WO2022006095A3 (en) Mosaic hiv-1 envelopes to induce adcc responses